Jasper Ther­a­peu­tics sees a stock boost af­ter sick­le cell da­ta re­lease; Newron lifts the veil on da­ta for schiz­o­phre­nia treat­ment

Jasper Ther­a­peu­tics is hav­ing a good start to the new year as it un­veils da­ta from its Phase I/II tri­al in­ves­ti­gat­ing the ad­di­tion of its an­ti-c-KIT mon­o­clon­al an­ti­body, known as briquil­imab, to an ex­ist­ing bone mar­row trans­plan­ta­tion reg­i­men for pa­tients with sick­le cell dis­ease (SCD) and be­ta tha­lassemia.

Ac­cord­ing to Jasper, the goal of the tri­al is to see if adding the an­ti­body would lead to a high­er per­cent­age of donor stem cell en­graft­ment with­out the in­creased tox­i­c­i­ty. The study it­self on­ly looked at a to­tal of three pa­tients with sick­le cell dis­ease. How­ev­er, all three par­tic­i­pants who were treat­ed were suc­cess­ful­ly en­graft­ed, ac­cord­ing to Jasper, and had no ad­verse ef­fect re­lat­ed to briquil­imab. All the pa­tients were al­so suc­cess­ful­ly en­graft­ed with­in a 12- to 16-day pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER